Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.19.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Cash flows from operating activities    
Net loss $ (916,958) $ (1,859,991)
Adjustments to reconcile net loss to net cash used in operating activities:    
Accrued income on marketable securities 2,314 (13,955)
Depreciation and amortization 15,437 56,452
Reserve for obsolete inventory 24,460
Reserve for doubtful accounts 4,247
Amortization of deferred compensation 3,469
Share based compensation to employees - options 2,712
Share based compensation to an employee 11,636
Share based compensation to directors - restricted stock units 3,906 5,175
Share based compensation to non-employees - restricted stock 12,545
Changes in assets and liabilities:    
(Increase)/decrease in trade receivables (152,445) 547,773
(Increase)/decrease in deposits and other receivables 9,347 (46,148)
Increase in inventories (16,033) (50,795)
(Increase)/decrease in prepaid expenses 182,655 (76,570)
Increase/(decrease) in trade and other payables 107,159 (405,499)
Net cash used in operating activities (748,735) (1,800,372)
Cash flows from investing activities    
Purchases of property, plant and equipment (37,827)
Purchases of marketable securities (30,018) (3,972,386)
Proceeds from sale of marketable securities 852,520 302,095
Net cash provided by/(used in) investing activities 822,502 (3,708,118)
Cash flows from financing activities    
Net proceeds from exercise of warrants for common stock 5,717,325
Net cash provided by financing activities 5,717,325
Net increase in cash and restricted cash 73,767 208,835
Cash and restricted cash at beginning of period 681,755 438,432
Cash and restricted cash at end of period 755,522 647,267
Cash paid for:    
Interest
Income Taxes
Supplemental Schedule of Non-Cash Financing and Investing Activities    
Net unrealized gains/(losses) on marketable securities 29,343 (16,843)
Conversion of Series B Preferred Stock to common shares $ 1,755,000